155 related articles for article (PubMed ID: 37222093)
41. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
42. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A
Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636
[TBL] [Abstract][Full Text] [Related]
43. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
[TBL] [Abstract][Full Text] [Related]
44. New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell Leukemia.
Soong D; Taylor J
NEJM Evid; 2023 Oct; 2(10):EVIDe2300173. PubMed ID: 38320184
[TBL] [Abstract][Full Text] [Related]
45. BRAF in the cross-hairs.
Geyer MB; Abdel-Wahab O; Tallman MS
Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
[TBL] [Abstract][Full Text] [Related]
46. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
47. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
48. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
49. A case of Erdheim-Chester disease with spinal cord compression and sphenoid sinus involvement.
Bunaux K; Sevestre H; Emile JF; Capel C; Chenin L; Peltier J
Neurochirurgie; 2018 Dec; 64(6):439-441. PubMed ID: 30274919
[TBL] [Abstract][Full Text] [Related]
50. Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.
Ruan GJ; Goyal G; Shah MV; Cohen-Aubart F; Amoura Z; Straetmans N; Benameur N; Haroche J; Go RS;
Pancreas; 2021 Jan; 50(1):e6-e8. PubMed ID: 33370037
[No Abstract] [Full Text] [Related]
51. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.
Dietrich S; Pircher A; Endris V; Peyrade F; Wendtner CM; Follows GA; Hüllein J; Jethwa A; Ellert E; Walther T; Liu X; Dyer MJ; Elter T; Brummer T; Zeiser R; Hermann M; Herold M; Weichert W; Dearden C; Haferlach T; Seiffert M; Hallek M; von Kalle C; Ho AD; Gaehler A; Andrulis M; Steurer M; Zenz T
Blood; 2016 Jun; 127(23):2847-55. PubMed ID: 26941398
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of BRAF-Inhibitor Therapy in BRAF
Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
[TBL] [Abstract][Full Text] [Related]
53. Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.
Salama HA; Jazieh AR; Alhejazi AY; Absi A; Alshieban S; Alzahrani M; Alaskar A; Gmati G; Damlaj M; Abuelgasim KA; Alghamdi A; Alahmari B; Almugairi A; Alzahrani H; Bazarbachi A; Musa MOH; Goyal G
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e66-e75. PubMed ID: 32943371
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
[No Abstract] [Full Text] [Related]
55. Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.
Roeser A; Cohen-Aubart F; Breillat P; Miyara M; Emile JF; Charlotte F; Donadieu J; Amoura Z; Haroche J
Haematologica; 2019 Nov; 104(11):e502-e505. PubMed ID: 30923093
[No Abstract] [Full Text] [Related]
56. Erdheim Chester disease with appendicular skeletal, renal and pleural involvement responding to Zelboraf (BRAF inhibitor) treatment: case report.
Borys D; Nystrom L; Song A; Lomasney LM
Skeletal Radiol; 2016 Oct; 45(10):1397-402. PubMed ID: 27423231
[TBL] [Abstract][Full Text] [Related]
57. Low-dose vemurafenib monotherapy in
Ruan GJ; Hazim A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Leuk Lymphoma; 2020 Nov; 61(11):2733-2737. PubMed ID: 32608295
[No Abstract] [Full Text] [Related]
58. Sarcoidosis occurring during BRAF/MEK inhibitors is associated with paradoxical ERK activation in Erdheim-Chester patients.
Amoura A; Haroche J; Emile JF; Barete S; Helias-Rodzewicz Z; Charlotte F; Maisonobe T; Amoura Z; Cohen Aubart F
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e348-e350. PubMed ID: 31002424
[No Abstract] [Full Text] [Related]
59. Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation.
Bentel JM; Thomas MA; Rodgers JJ; Arooj M; Gray E; Allcock R; Fermoyle S; Mancera RL; Cannell P; Parry J
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28455460
[TBL] [Abstract][Full Text] [Related]
60. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
